Dora Wirth Languages | Pharmaceutical Translations https://www.dwlanguages.com Need global life science solutions? Rely on us. Problem solved. Thu, 22 Feb 2018 13:33:50 +0000 en-US hourly 1 https://wordpress.org/?v=4.8.5 The Landscape for CROs post Brexit: An Update https://www.dwlanguages.com/cros-post-brexit/ https://www.dwlanguages.com/cros-post-brexit/#respond Thu, 22 Feb 2018 13:33:50 +0000 https://www.dwlanguages.com/?p=2303 UK still a key player The Clinical & Contract Research Association (CCRA) held a one-day session entitled The Landscape for CROs post Brexit—An Update on 31 January 2018 at the Royal Society of Medicine in London, one year on from a similar event in January 2017. The session was chaired by Dr Virginia Acha, Executive

The post The Landscape for CROs post Brexit: An Update appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
UK still a key player

The Clinical & Contract Research Association (CCRA) held a one-day session entitled The Landscape for CROs post Brexit—An Update on 31 January 2018 at the Royal Society of Medicine in London, one year on from a similar event in January 2017. The session was chaired by Dr Virginia Acha, Executive Director, Global Regulatory Policy, MSD. While some of the passions surrounding Brexit may have calmed over the past year, there still remains much of the uncertainty about what Brexit means for the clinical research sector in the UK.

Throughout the day, the speakers emphasised the country's role in clinical research. For instance, 70% of EU investigational medicinal products (IMPs) are released from the UK; there are currently 1500 ongoing EU clinical trials sponsored by the UK; 1300 authorised EU products have been tested and released from the UK.

Thus, maintaining UK expertise and influence in life sciences and clinical research outside a large trading bloc is an important aim post-Brexit.

Brexit at a cost for life sciences

One uncertainty after the UK leaves the EU concerns the regulatory framework for clinical trials. A stand-alone UK regulatory model post-Brexit would mean an additional regulatory burden, which would increase costs. Negotiating mutual recognition with the EU would also take a lot of time. It is also important to maintain pharmacovigilance cooperation: if the UK is unable to access centralised databases, patients might suffer.

Safeguarding key interests

Dr John Poland, consultant to the Association of Clinical Research Organisations (ACRO), outlined what ACRO believes the UK needs to do, such as securing long-term, predictable access to funding and international collaboration for scientific research and improving tax benefits and intellectual property protection to encourage clinical research in the UK. Finally, the UK needs to establish a more collaborative environment between the NHS and industry. This would help support innovative product use in the clinical trial setting and modernise the clinical research process.

Dr Poland highlighted the need to ensure an unhindered product supply chain, since about 40% of IMPs in clinical trials being run in the EU are made in the UK. Additional requirements and/or costs to export IMPs to the EU will mean manufacturing capacity will transfer to EU countries. Dr Poland also emphasised the need for an unrestricted flow of personal data. When the Clinical Trial Regulation comes into application, there will be a single submission for clinical trials in the EU via a portal. If the UK is unable to participate in these new processes (and the date for the clinical trial portal becoming operational is believed to be the second half of 2019), it will become a less appealing place for clinical trials in Europe.

CROs preparing for the divorce

Dr Ben Quarterly, Executive Director, Global Clinical Development at Covance outlined the perspective of a global clinical research organisation (CRO) on Brexit. He explained Covance is monitoring developing thinking in London, Brussels and elsewhere and has an internal Brexit taskforce with defined roles and responsibilities. Experts need to analyse the potential impacts of Brexit, while CROs need to be ready to capitalise, prepare, engage and inform regarding the whole process. He pointed out potential opportunities: Brexit may allow a faster path for starting clinical trials and enable leverage of the overall benefits of the UK. There is already a positive focus on life sciences, research and innovation in the UK and the government is motivated to support access to international talent and to develop young people through the sciences.

Dr Lincoln Tsang, a partner at Arnold & Porter Kaye Scholer LLP, took us through the minefield of the legal landscape and the consequences of "no deal" and stressed the complexity of disentanglement from the EU and that Britain’s future relationship with the EU is still very much guesswork. Annabelle Malins, from the Department of International Trade, emphasised the importance of providing certainty and continuity to UK business post-Brexit. To do this, all negotiation outcomes need to be taken into consideration.

Unanswered questions

The day ended with a panel discussion reviewing the various issues raised during the meeting. A practical problem arising from the questions concerns the shipment of clinical trial supplies (which are often time- and temperature-sensitive) from EU countries to the USA. These issues often include hold-ups at customs. When the UK leaves the Union, will there be similar problems? Will these put patients at risk, especially if they cannot access their treatment straight away due to customs delays? Another potential problem is tariff imposition: will this lead to loss of investor confidence in the UK life sciences field?

In other words, when it comes to Brexit, there are still more questions than answers.

The post The Landscape for CROs post Brexit: An Update appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/cros-post-brexit/feed/ 0
Spotlight on Cuba: How fostering business partnerships with Cuba could benefit the UK and global health industries https://www.dwlanguages.com/spotlight-on-cuba-business/ https://www.dwlanguages.com/spotlight-on-cuba-business/#respond Thu, 15 Feb 2018 11:28:24 +0000 https://www.dwlanguages.com/?p=2294 Recently, DWL met with a delegation from the Life Sciences sector in Cuba, as part of an initiative by the UK Department of International Trade. At the meeting were representatives from the Cuban Chamber of Commerce and other governmental bodies, as well as pharmaceutical and biotechnology agencies including BioCubaFarma, CECMED, CIGB and CIM-CIMAB. The aim

The post Spotlight on Cuba: How fostering business partnerships with Cuba could benefit the UK and global health industries appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
Recently, DWL met with a delegation from the Life Sciences sector in Cuba, as part of an initiative by the UK Department of International Trade. At the meeting were representatives from the Cuban Chamber of Commerce and other governmental bodies, as well as pharmaceutical and biotechnology agencies including BioCubaFarma, CECMED, CIGB and CIM-CIMAB.

The aim was to discuss developments and opportunities in the Cuban health markets. Delegates identified potential avenues for regional and international partnerships that would promote Cuban advancements in human, animal and plant health which could be of global benefit.

Cuba’s pharma success story

Despite the decades-long US embargo, Cuba is at the forefront of innovation and quality in the pharmaceutical and biotechnology industries. This is partly due to Castro’s encouraging scientific research through state measures and investment to counter the effects of the blockade. Today these measures include increasing inward investment in healthcare, and the work of BioCubaFarma, which coordinates the activities of several pharmaceutical institutions.

The result is that Cuba has an excellent public health service despite being a developing country with low average income. It is also the first country to eliminate mother-to-child HIV.

Cuba claims also to be a world leader in recombinant vaccines, with promising drug research in oncology and scar repair. Crucially, its researchers are actively involved in every stage of drug development.

Finally, their business models favour national collaboration instead of individual competition. What this entails is greater consistency and fewer barriers from research through to authorisation.

Why Cuba is ripe for business

Cuban decision-makers are keen to capitalize on their country’s position in healthcare by providing attractive incentives for foreign investment. For example, they claim to offer foreign investors in Cuban life sciences tax free dividends for the first 10 years. They are also claiming to offer marketing rights to foreign companies in exchange for funding clinical trials – at present Cuba is running 23 such trials in 35 countries.

Although its industry is state-owned, Cuba is open to private investment. CIM have created CIMAB SA to act like a private company in order to accept funding, develop IP “out-licenses” and pursue joint ventures outside the country. For instance, Cuba runs joint marketing ventures on monoclonal antibodies with China, Thailand and Singapore. It also has good working relationships with Russia and India, providing further possible avenues for joint research and collaboration.

Local challenges 

There are however certain challenges to overcome in light of future alliances. For instance, Cuba has poor IT infrastructure, with virtually no broadband internet access and few Wi-Fi hotspots. The use of mobile phones is limited, with no mobile Internet access as of yet. Moreover, Cuba is a cash market and credit cards are not prevalent among the population. They do accept credit cards as long as they are not issued by an American bank (Sonegate Bank and Banco Popular de Puerto Rico being the only notable exceptions).

Another challenge facing life science companies and investors interested in Cuba is the language barrier. Decision-makers claim communication can be slow and fraught with misunderstanding when working with developing nations.

Global solutions and rewards

One possible solution to the language barrier is bilingual facilitation by a language service provider such as DWL. Given our expertise in medical, pharmaceutical and regulatory documentation, we welcome opportunities to facilitate understanding for agencies and governmental bodies seeking partnerships with Cuban stakeholders.

Despite its infrastructure issues, Cuba relies heavily on open source software. This means there are low barriers to entry to the health market provided that services are free to patients. There are also considerable opportunities for companies who can turn raw patient data into health technology, with important implications for big data sectors.

The rewards for partnering with Cuba in the pharmaceutical and biotechnology sectors appear to be considerable. Foreign investment will bring much-needed drugs to broader markets, improve infrastructure and facilities, create jobs and stimulate further research. Cuba can also serve as a gateway into Latin America for drug companies and investors in the UK and worldwide, meaning access to new markets and new development opportunities.

Lastly, it is highly possible Brexit might reduce the UK's access to European markets. It is thus vital that the UK secures trade partnerships with other key markets to foster innovation and support its economy. With a first-class reputation in Life Sciences and an openness to trade, Cuba looks promising.

The post Spotlight on Cuba: How fostering business partnerships with Cuba could benefit the UK and global health industries appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/spotlight-on-cuba-business/feed/ 0
EMA Human Medicines Highlights 2017 Out Now https://www.dwlanguages.com/ema-publishes-highlights-2017/ https://www.dwlanguages.com/ema-publishes-highlights-2017/#respond Fri, 26 Jan 2018 12:30:17 +0000 https://www.dwlanguages.com/?p=2275 The European Medicines Agency (EMA) has published its yearly overview of key recommendations for 2017, covering the authorisation of new medicines and related safety monitoring. The overview reveals the EMA recommended 92 medicines for approval. Of these, 35 contained new active substances never before authorized in the European Union. Most of these medicines are aimed

The post EMA Human Medicines Highlights 2017 Out Now appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
The European Medicines Agency (EMA) has published its yearly overview of key recommendations for 2017, covering the authorisation of new medicines and related safety monitoring.

The overview reveals the EMA recommended 92 medicines for approval. Of these, 35 contained new active substances never before authorized in the European Union. Most of these medicines are aimed at the treatment of cancer and infections, although significant advancements have also been made in neurology, endocrinology and gastroenterology, including applications for Crohn’s disease patients.

With the publication of the 2017 highlights, Dora Wirth Languages (DWL) is proud to have worked on many of the featured medicines approved last year. Our work entailed translating the product information for each of the 24 languages of the EU/EEA member states, managing project delivery and ensuring compliance with EMA guidelines. DWL contributed to a number of new applications and extensions, as well as several variations for existing products.

Read the EMA summary in full here:

bit.ly/EMAHighlights17

The post EMA Human Medicines Highlights 2017 Out Now appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/ema-publishes-highlights-2017/feed/ 0
What Makes A Good Translation for Regulatory Submission (And How To Avoid Being Let Down) https://www.dwlanguages.com/makes-good-translation-regulatory-submission-avoid-let/ https://www.dwlanguages.com/makes-good-translation-regulatory-submission-avoid-let/#respond Tue, 31 Oct 2017 13:12:52 +0000 http://www.dwlanguages.com/?p=2048 When you’ve worked hard to build your reputation, the last thing you need is your translation service provider letting you down. Without a full understanding of what makes a good translation, selecting your provider can quite literally be a gamble - especially with any extra costs associated with delays to submissions. To take the risk

The post What Makes A Good Translation for Regulatory Submission (And How To Avoid Being Let Down) appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
When you’ve worked hard to build your reputation, the last thing you need is your translation service provider letting you down. Without a full understanding of what makes a good translation, selecting your provider can quite literally be a gamble - especially with any extra costs associated with delays to submissions. To take the risk out of regulatory translations, we’d like to share the most important factors in ensuring you get a good translation.

First things first - the highest-quality translations for submission to the EMA will always come from a highly qualified, experienced translator with the relevant medical and scientific knowledge. If you find yourself looking to cut costs by sourcing less experienced translators who don’t specialize in translating for the medical/pharmaceutical industry, think twice. Inaccurate and inconsistent translations will cost you far more in the long run. Any rejection of a translated PI at the last hurdle of your MA application not only reflects poorly on your reputation, but there is also the risk to patient safety to consider, should any errors slip through unnoticed. A specialist provider understands the serious implications of any errors or ambiguities, so you can have peace of mind knowing there will be a thorough and extensive quality control process in place.

Secondly, the best translations will come from providers with extensive experience in regulatory processes. All professionals involved in the translation process should have an excellent knowledge of the regulatory framework, documents and procedures. An in-depth understanding of your job means that your provider has a clear and supportive grasp of your needs and expectations, for example knowing when and how to use key terminology. They should demonstrate sound knowledge of the appropriate terminology and regulatory standard text and an awareness of the regulatory timetable and implications of out-of-scope changes to product information during variations or last-minute requests in the 5-day window.

As well as understanding the medical, scientific and regulatory standards and expectations, it is essential for your provider to have linguistic competence in both source and target languages. It really pays to check that your translators are required to translate into their mother tongue only. Translations provided by non-native speakers of the target language are likely to sound stilted, wooden and non-idiomatic, no matter how competent the linguist is. Note that the ISO translation standard 17100 imposes no requirement of using native speakers of the target language, so do check with your language service provider.

No matter how well your linguists rank on linguistic competency and knowledge of the subject matter, let’s not forget that accuracy is of the essence. This includes a faithful translation of the approved core text and consistent style that adheres to the conventions and expectations of the relevant regulatory bodies. Make sure your translation provider has robust and meaningful quality-control measures in place that aren’t relying purely on mechanical tools.

You may think it is fair to assume that all translations are fed into a machine these days, but in fact it is only careful (not universal) use of translation software that can guarantee quality and consistency, when overseen by human professionals with skill and experience in their subject matter.

Finding a service you can truly rely on will give you peace of mind for your submissions (let’s face it, they are stressful enough), making it easy to convince your procurement department of the worthwhile investment.

The post What Makes A Good Translation for Regulatory Submission (And How To Avoid Being Let Down) appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/makes-good-translation-regulatory-submission-avoid-let/feed/ 0
BREXIT: WHAT LIES AHEAD FOR THE UK LIFE SCIENCES SECTOR? https://www.dwlanguages.com/brexit-lies-ahead-uk-life-sciences-sector/ https://www.dwlanguages.com/brexit-lies-ahead-uk-life-sciences-sector/#respond Thu, 02 Feb 2017 10:30:46 +0000 http://www.dwlanguages.com/?p=2004 BREXIT: What lies ahead for the UK Life Sciences sector? DWL has received several questions about Brexit recently from translators but there is currently little hard information we can give them. What we do know from the government is that Brexit means Brexit...but Brexit means what for the UK's life sciences sector? This was one

The post BREXIT: WHAT LIES AHEAD FOR THE UK LIFE SCIENCES SECTOR? appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
BREXIT: What lies ahead for the UK Life Sciences sector?

DWL has received several questions about Brexit recently from translators but there is currently little hard information we can give them. What we do know from the government is that Brexit means Brexit...but Brexit means what for the UK's life sciences sector? This was one of the topics covered in a 2-day meeting of the Clinical & Contract Research Association (CCRA) held at the Royal Society of Medicine in London on 24 and 25 January 2017 and attended by the CEO of DWL, Samuel J. Wirth, and the Medical Director, Dr Iain Matheson.

 

Day 1 (entitled UK Clinical Research: A Professional Awareness Update) began with a talk by Matthew Speers, CEO of the Life Sciences Organisation, part of the Department for International Trade. He pointed out that the life sciences sector in the UK is very vibrant, with 220,000 employees, more than 5600 companies and a turnover of £61 billion and emphasised the need to promote the UK and to drive inward investment. Many overseas companies (especially in the US) see the UK as the natural stepping stone into Europe but this advantage has now been lost with Brexit, possibly to the benefit of Ireland or Germany. The role of the Medicines and Health Products Regulatory Agency (MHRA) will need to evolve – will it develop closer relationships with the US Food and Drug Administration (FDA) or relationships outside the EU (e.g. with Australia and New Zealand)? Questions for which there are not yet any answers... There is also uncertainty over what the US approach will be, now that Donald Trump is in the White House. Matthew Speers pointed out that the National Health Service (NHS) should be viewed as an asset, but that there might not be the necessary skills available due to the immigration policy post-Brexit. Over the two days, many speakers and delegates referred to the NHS as a "unique selling point" for the UK life sciences sector because of the availability of a huge amount of data in a single organisation.

 

Dr Martin O'Kane, Head of the Clinical Trials Unit at the MHRA, provided an update on the progress of the new EU Clinical Trials Regulation on Day 1. The need for a regulation has arisen from the failings of the Clinical Trials Directive, which has in some ways hampered research. The regulation will not become effective until the EU portal for processing clinical trial applications and the database have been audited and found to be suitable. User testing on the portal is currently taking place and will continue in 2017. The audit is scheduled for autumn this year. If the audit outcome is favourable, the EU Clinical Trials Regulation will come into effect by October 2018. It is unclear how Brexit will affect implementation in the UK. It is possible that the regulation will roll-over after any repeal act especially as the regulation contains many proposals favoured by the UK. As with all things Brexit, only time will tell...

 

A show of hands at the start of Day 2 entitled UK Clinical Research: The Landscape for CROs Post-Brexit indicated that most attendees thought that the UK would weather the Brexit storm and that it was not all doom and gloom. Professor Richard Barker, OBE, Director of the Centre for the Advancement and Sustainability of Medical Innovation, pointed out that the UK has some of the world's top clinicians, that with the fall in the pound's value the UK has become a cheaper market and that being a relatively small market the UK needs to be distinctive. The attractiveness of the UK as a place for life sciences organisations to do business needs to be promoted.

 

Professor Angus Dalgleish, Professor of Oncology at St George's Hospital, London, and an unsuccessful parliamentary candidate for UKIP in the 2015 General Election, offered a different view. He felt Brexit had led to a lot of hysteria and that it offered tremendous opportunities for the life sciences sector in the UK. He pointed out that the training of doctors had suffered because of the European Working Time Directive as it deprived them of valuable clinical experience and that the EU Clinical Trials Directive had been detrimental to clinical research in the UK, especially as it was interpreted very rigorously here and had meant some research had had to be abandoned. He reminded us that long before the Maastricht and Lisbon treaties there had been a lot of cooperation at European level, such as the European Space Agency, the European Molecular Biology Laboratory, the European Organization for Nuclear Research (CERN) and, of course, Concorde and Airbus.

 

Stephen Dorrell, Chair of the NHS Confederation and a former Secretary of State for Health in John Major's government in the 1990s, rounded off the Brexit debate. He believed that a quick, innovative and flexible approach to clinical trials was needed so that patients can benefit internationally. A nationalistic regulatory view is therefore contrary to his belief that innovations in healthcare should be implemented as widely as possible. As he sees it, an international research environment functions best and this of course requires the availability of a skilled workforce, something that is likely to be a stumbling block if a more rigorous immigration policy is enforced post-Brexit. He tempered the enthusiasm of some of the delegates about the NHS. Although it is a key national idea, in Dorrell's view, the NHS should be viewed not as a single organisation but as many smaller organisations.

 

We hope to be able to give an update on the implications of Brexit later in the year.

Brexit

The post BREXIT: WHAT LIES AHEAD FOR THE UK LIFE SCIENCES SECTOR? appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/brexit-lies-ahead-uk-life-sciences-sector/feed/ 0
DWL is hiring: Full time Project Manager required https://www.dwlanguages.com/dwl-hiring-full-time-project-manager-required/ https://www.dwlanguages.com/dwl-hiring-full-time-project-manager-required/#respond Tue, 17 Jan 2017 07:38:23 +0000 http://www.dwlanguages.com/?p=1992 DWL is hiring! We are looking for an experienced Project Manager to provide extra support for a busy translation service provider specialising in the life sciences. Job description: As a Project Manager at DWL you will: Operate within DWL’s quality management system and ISO 9001 certification. Handle key accounts as part of the project management

The post DWL is hiring: Full time Project Manager required appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
DWL is hiring!

We are looking for an experienced Project Manager to provide extra support for a busy translation service provider specialising in the life sciences.

Job description:

As a Project Manager at DWL you will:

  • Operate within DWL’s quality management system and ISO 9001 certification.
  • Handle key accounts as part of the project management team.
  • Be responsible for quotations, order handling and quality control of the translations.
  • Be working on projects in the medical / pharmaceutical field, including regulatory projects for submission to the European Medicines Agency (involving up to 24 languages).
  • Set up and process all compatible translation projects in memoQ.
  • Be responsible for the final MS-Word processing of the translations to ensure that they respect either the original format or the standard requested by the client.
  • When required, work paid overtime (evenings, occasional weekends).

 

Profile:

  • We are looking for a committed and dynamic person with excellent communication skills and strong knowledge of both spoken and written English and project management experience of ideally 2 years or more.
  • Languages: knowledge of at least 2 European languages other than English is essential, and some understanding of the nature of scientific publications and documents, particularly regulatory/pharmaceutical/medical documentation, is a bonus.
  • Regulatory: familiarity with EMA templates and standard terminology for this type of documentation would be ideal but is not essential.
  • Accuracy: accurate and thorough quality control is essential to ensure that all the material delivered to clients complies with DWL quality standards.
  • IT: computer literacy and strong MS-Word processing skills are essential as the project management occasionally requires the preparation/finalisation of layout/format for the translated documents. Must be experienced in working with a CAT tool (preferably memoQ).
  • Desirable: flexibility and positive thinking to work in a small busy team always striving to find creative solutions to optimise client and translator satisfaction whilst working in an enjoyable environment.

 

Start date:

ASAP

 

The Team:

Based in Hammersmith, we are a team of 12 staff.

The post DWL is hiring: Full time Project Manager required appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/dwl-hiring-full-time-project-manager-required/feed/ 0
New Arrival: Kate Harvey https://www.dwlanguages.com/new-arrival-kate-harvey/ https://www.dwlanguages.com/new-arrival-kate-harvey/#respond Thu, 26 May 2016 11:20:35 +0000 http://www.dwlanguages.com/?p=1627 As 2016 rolls firmly on, it's time to introduce another new arrival to our team with whom you may not yet be familiar. Kate Harvey joined us in October 2015 as Project Support Assistant, and has supported the DWL Project Management team in diverse ways ever since. From aligning translation memories to performing visual checks on Product Information, Kate's first

The post New Arrival: Kate Harvey appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
As 2016 rolls firmly on, it's time to introduce another new arrival to our team with whom you may not yet be familiar. Kate Harvey joined us in October 2015 as Project Support Assistant, and has supported the DWL Project Management team in diverse ways ever since. From aligning translation memories to performing visual checks on Product Information, Kate's first year has been varied, and our team has already benefited from her focused work ethic and unflappable nature.

As is now customary, we thought we would ask some searching and personal questions and find out what makes Kate tick.

DWL: Where do you call home, Kate?

I grew up on a Devonshire Dairy farm, amongst a big family, and even more cows and fields, so I think that will always be home for me. However, I also enjoyed living in Birmingham, sunny Spain and not-so-sunny Portugal as part of my 4 year degree at the University of Birmingham. Since joining the DWL team in October 2015 I have lived in London and I am currently relishing exploring all that the city has to offer.

DWL: Which languages do you speak?

I am a native English speaker and also speak Spanish and Portuguese thanks to my four-year Hispanic Studies degree. Spanish is my particular strength having spent some time prior to my Erasmus year working as an au pair in Spain. I hugely enjoyed living in Valencia, Spain and then Coimbra, Portugal during my year studying abroad and found these the most valuable experiences for language learning. My appreciation for the distinct cultures of the two countries (and climates!) has inspired my ambition to pursue a career in languages.

DWL: When did you perform your first ever translation and can you remember what it was about?

I performed my first translation project from Spanish to English in final year at University, through a module entitled Translation Theory and Practice. Our task was to pick a passage of 1000 words, which had to be as bizarre and as complex as possible, and translate it alongside an analytical commentary to justify our translation decisions. I really enjoyed the project, and chose a section from crime fiction author Eduardo Mendoza’s  ‘El laberinto de las aceitunas’ (really quite a strange yet enjoyable read, if anyone is considering). It was certainly challenging translating analogies and irony which relied upon their cultural roots for comic effect. However, it gave me a great insight into the many challenges involved in creating a quality translation and in the end I was glad to have chosen such a difficult, niche passage to translate.

DWL: How easy/difficult was it to find work after University?

After thoroughly enjoying my languages degree, especially the modules in translation, I was sure I wanted to learn more about the translation industry. Through my research I found a concentration of translation companies in London and was excited by the prospect of moving to the 'Big Smoke'. My attention was initially drawn to DWL due to their specific focus on the interesting field of medical translation, along with their promise of a highly professional yet personable service. After a couple of months of searching and submitting applications, I was thrilled to be offered a translation aptitude test by DWL. I was travelling through Europe at the time, but thankfully the shaky Wi-Fi at an internet cafe in the South of France pulled through and I was offered a 3 month internship. The DWL team made me feel very welcome and having gladly accepted a permanent contract after my internship, I am enjoying the increasing responsibility and learning curve of the transition from learning translation theory, to managing translation projects in practice.

DWL: What’s your favourite pastime?

I enjoy keeping active, and I’m a big fan of the beach and the outdoors. I’m also a lover of music, and frequently go to concerts and gigs. So in a nutshell, a run along the coast whilst listening to some good music is probably one of my favourite things to do.

DWL: Did you make a new year’s resolution for 2016, and have you managed to keep it?

I´m not one for making huge life-altering changes at New Year, and I am certainly not going to be giving up chocolate any time soon, but I have made a conscious effort to get into healthy, interesting cooking. Inspired by the innumerable food markets of my new hometown, I have produced some good and some not-so-good experimental dishes. Highlights have included sweet potato brownies, courgette and chocolate cake and, most recently, coconut, cashew and date energy bars which powered my sister and I through the Bath Half Marathon.

DWL: Who is your hero?

Although perhaps lesser known than Nelson Mandela and Mother Teresa, Granny Harvey is without a doubt my most influential heroine. She’s nearly 84, walks absolutely miles over rolling hills every day (never without her hyperactive Jack Russell by her side, as none of her friends can keep up), is the bubbliest person I know, and is not on one bit of medication! She truly inspires me to appreciate the vitality of life.

Thank you, Kate!

FullSizeRender

The post New Arrival: Kate Harvey appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/new-arrival-kate-harvey/feed/ 0
DWL are exhibiting at BioTrinity 2016 https://www.dwlanguages.com/biotrinity-2016/ https://www.dwlanguages.com/biotrinity-2016/#respond Fri, 22 Apr 2016 15:21:03 +0000 http://www.dwlanguages.com/?p=1591 Next week (26th & 27th April) you'll find DWL exhibiting at BioTrinity 2016 - Europe's leading investment and biopartnering conference. We're on stand number 39 in the exhibition hall. The floorplan can be found here: http://www.biotrinity.com/sites/default/files/BioTrinity%202016%20Exhibition%20Floor%20Plan%20Zoned_0.pdf Kim and Beatriz look forward to meeting you there!   For more information, please see: http://www.biotrinity.com/

The post DWL are exhibiting at BioTrinity 2016 appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
Next week (26th & 27th April) you'll find DWL exhibiting at BioTrinity 2016 - Europe's leading investment and biopartnering conference.

We're on stand number 39 in the exhibition hall.

The floorplan can be found here:

http://www.biotrinity.com/sites/default/files/BioTrinity%202016%20Exhibition%20Floor%20Plan%20Zoned_0.pdf

Kim and Beatriz look forward to meeting you there!

 

For more information, please see: http://www.biotrinity.com/

BioTrinity 2016

The post DWL are exhibiting at BioTrinity 2016 appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/biotrinity-2016/feed/ 0
DIA EuroMeeting 2016 https://www.dwlanguages.com/dia-euromeeting-2016/ https://www.dwlanguages.com/dia-euromeeting-2016/#respond Mon, 04 Apr 2016 14:58:04 +0000 http://www.dwlanguages.com/?p=1570 Join DWL at the 28th Annual DIA Euromeeting, being held from the 6th to 8th April in Hamburg, Germany. The theme for the DIA EuroMeeting 2016 is "INnovation: Do You Win by Being IN? — In a world in which new therapies are being developed at a phenomenal rate, is innovation always the answer?" DWL will

The post DIA EuroMeeting 2016 appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
Join DWL at the 28th Annual DIA Euromeeting, being held from the 6th to 8th April in Hamburg, Germany.

The theme for the DIA EuroMeeting 2016 is "INnovation: Do You Win by Being IN? — In a world in which new therapies are being developed at a phenomenal rate, is innovation always the answer?"

DWL will be exhibiting on Stand K4. Please stop by to say hello and to chat to us about the challenges you are facing with your multilingual healthcare content.

DIA EuroMeeting 2016

 

Why attend the DIA EuroMeeting 2016? Read more here: http://www.diaglobal.org/en/flagship/euromeeting-2016/about/why-attend

 

 

The post DIA EuroMeeting 2016 appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/dia-euromeeting-2016/feed/ 0
STUMBLING ON SUCCESS: Drugs discovered by accident https://www.dwlanguages.com/drugs-discovered-by-accident/ https://www.dwlanguages.com/drugs-discovered-by-accident/#respond Thu, 03 Mar 2016 17:37:17 +0000 http://www.dwlanguages.com/?p=1563 STUMBLING ON SUCCESS: Drugs discovered by accident Just as new words are coined and old ones evolve, so too does medical science evolve and improve in a non-linear fashion. In fact there are many great discoveries in medicine which resulted from strange or unfortunate circumstances, or which ended up having very different applications to those

The post STUMBLING ON SUCCESS: Drugs discovered by accident appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
STUMBLING ON SUCCESS: Drugs discovered by accident

Just as new words are coined and old ones evolve, so too does medical science evolve and improve in a non-linear fashion.

In fact there are many great discoveries in medicine which resulted from strange or unfortunate circumstances, or which ended up having very different applications to those originally intended.

For example:

Viagra (sildenafil citrate): One of the most famous modern accidental medical discoveries. The fastest selling drug of all time, this medicine is taken for erectile dysfunction, but it was originally prescribed for treatment of hypertension and angina. It is also used off-label as a cure for jet-lag! The drug is not without risk, however, as excessive use may cause deafness and/or blindness.

Minoxidil: This antihypertensive vasodilator medication was originally being tested on dogs as a treatment for ulcers. It failed to treat the ulcers, but instead was authorised by the FDA for testing as a treatment for hypertension, due to its powerful vasodilating properties. Subsequent studies with minoxidil showed unexpected hair growth in subjects, and today it is successfully used as the active ingredient in popular hair loss treatments.

Mustard gas (sulphur mustard): This blister-causing chemical is well known as a horrendous and damaging chemical warfare agent. However, did you know that tests on the white blood cell counts of mustard gas victims ultimately led physicians to discover its value as therapy for Hodgkin’s lymphoma? Eventually, a similar compound (nitrogen mustard) became the first cancer chemotherapy drug, marketed as Mustine.

Penicillin was among the first medicines to combat bacterial infections. Various scientists had noticed the curative properties of mould, and in 1928 Alexander Fleming reported that under the right conditions, Penicillium rubens would exude a substance with antibiotic properties. It is now the most commonly used antibiotic in the world!

Warfarin ‑ in the 1920s it was the scourge of livestock farms in North America and Canada and was later used as rat poison. Post-Depression farmers in North America and Canada, in those austere times, began letting their cattle graze on damp/mouldy sweet clover hay which in more affluent times would have been discarded. After previously healthy cattle began to die from bleeding, they discovered that coumarin found in the hay was to blame for what they had come to know as “sweet clover poisoning”. In 1948, it became used as a rodenticide, and was patented as “Warfarin”. Then in 1958, it was administered to General Dwight Eisenhower who had just suffered a myocardial infarction, and later proved in clinical trials to increase survival following deep venous thrombosis and pulmonary embolism. Today it is the most widely prescribed oral anticoagulant drug in the US - all thanks to those few unfortunate cattle back in the 1920s! There is now a new generation of anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) which are proving to have some advantages for patients over warfarin.

Do you have any favourite drug discovery stories to share?

 

The post STUMBLING ON SUCCESS: Drugs discovered by accident appeared first on Dora Wirth Languages | Pharmaceutical Translations.

]]>
https://www.dwlanguages.com/drugs-discovered-by-accident/feed/ 0